Jounce Therapeutics, Inc.
SEC CIK 1640455 · JNCE · last insider filing 2023-05-05
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Tang Kevin C | Director | filed 2023 - 2023 |
| Murray Richard /CA/ | Director · CEO and President | filed 2017 - 2023 |
| Karsen Perry A | Director | filed 2017 - 2023 |
| Duncan Barbara Gayle | Director | filed 2017 - 2023 |
| Kamen Robert | Director | filed 2017 - 2023 |
| Diaz Luis | Director | filed 2017 - 2023 |
| Iannone Robert | Director | filed 2020 - 2023 |
| Raythatha Jigar | Director | filed 2021 - 2023 |
| Salter-Cid Luisa | Director | filed 2021 - 2023 |
| Higgons John Duncan | Director | filed 2017 - 2022 |
| Tepper Robert I | Director | filed 2017 - 2021 |
| Pfeffer Cary | Director | filed 2017 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Drapkin Kimberlee C | President, CFO and Treasurer | filed 2017 - 2023 |
| Cole Hugh M | Chief Operating Officer | filed 2017 - 2023 |
| Trehu Elizabeth | Chief Medical Officer | filed 2017 - 2023 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.